PortfoliosLab logoPortfoliosLab logo
TOI vs. ANRO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TOI vs. ANRO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in The Oncology Institute, Inc. (TOI) and Alto Neuroscience, Inc (ANRO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TOI achieves a 41.29% return, which is significantly higher than ANRO's 37.30% return.


TOI

1D
0.40%
1M
9.59%
YTD
41.29%
6M
48.82%
1Y
119.65%
3Y*
107.87%
5Y*
10Y*

ANRO

1D
6.59%
1M
15.17%
YTD
37.30%
6M
24.31%
1Y
922.59%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

TOI vs. ANRO - Yearly Performance Comparison


2026 (YTD)20252024
TOI
The Oncology Institute, Inc.
41.29%1,052.10%-85.42%
ANRO
Alto Neuroscience, Inc
37.30%320.80%-80.77%

Correlation

The correlation between TOI and ANRO is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.27

Correlation (All Time)
Calculated using the full available price history since Feb 2, 2024

0.12

The correlation between TOI and ANRO shifts across timeframes, from 0.12 (all time) to 0.27 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

TOI:

$5.12B

ANRO:

$803.90M

EPS

TOI:

-$0.04

ANRO:

-$2.50

Total Revenue (TTM)

TOI:

$545.76M

ANRO:

$0.00

Gross Profit (TTM)

TOI:

$52.24M

ANRO:

-$421.00K

EBITDA (TTM)

TOI:

-$21.81M

ANRO:

-$74.36M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TOI vs. ANRO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TOI
TOI Risk / Return Rank: 7979
Overall Rank
TOI Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
TOI Sortino Ratio Rank: 8282
Sortino Ratio Rank
TOI Omega Ratio Rank: 7878
Omega Ratio Rank
TOI Calmar Ratio Rank: 8080
Calmar Ratio Rank
TOI Martin Ratio Rank: 7676
Martin Ratio Rank

ANRO
ANRO Risk / Return Rank: 9999
Overall Rank
ANRO Sharpe Ratio Rank: 100100
Sharpe Ratio Rank
ANRO Sortino Ratio Rank: 9999
Sortino Ratio Rank
ANRO Omega Ratio Rank: 9898
Omega Ratio Rank
ANRO Calmar Ratio Rank: 100100
Calmar Ratio Rank
ANRO Martin Ratio Rank: 100100
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TOI vs. ANRO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for The Oncology Institute, Inc. (TOI) and Alto Neuroscience, Inc (ANRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


TOIANRODifference
Sharpe ratioReturn per unit of total volatility

-5.76

Sortino ratioReturn per unit of downside risk

-3.33

Omega ratioGain probability vs. loss probability

1.27

1.72

-0.45

Calmar ratioReturn relative to maximum drawdown

2.42

27.26

-24.84

Martin ratioReturn relative to average drawdown

4.86

71.06

-66.20

TOI vs. ANRO - Sharpe Ratio Comparison

The current TOI Sharpe Ratio is 1.49, which is lower than the ANRO Sharpe Ratio of 7.25. The chart below compares the historical Sharpe Ratios of TOI and ANRO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

TOI vs. ANRO - Drawdown Comparison

The maximum TOI drawdown since its inception was -98.79%, which is greater than ANRO's maximum drawdown of -91.82%. Use the drawdown chart below to compare losses from any high point for TOI and ANRO.


Loading charts...

Drawdown Indicators


TOIANRODifference

Max Drawdown

Largest peak-to-trough decline

-98.79%

-91.82%

-6.97%

Max Drawdown (1Y)

Largest decline over 1 year

-49.79%

-34.20%

-15.59%

Max Drawdown (3Y)

Largest decline over 3 years

-94.82%

Current Drawdown

Current decline from peak

-53.90%

-11.83%

-42.07%

Average Drawdown

Average peak-to-trough decline

-73.98%

-53.23%

-20.75%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.70%

13.09%

+11.61%

Volatility

TOI vs. ANRO - Volatility Comparison

The current volatility for The Oncology Institute, Inc. (TOI) is 21.02%, while Alto Neuroscience, Inc (ANRO) has a volatility of 24.73%. This indicates that TOI experiences smaller price fluctuations and is considered to be less risky than ANRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TOIANRODifference

Volatility (1M)

Calculated over the trailing 1-month period

21.02%

24.73%

-3.71%

Volatility (6M)

Calculated over the trailing 6-month period

50.61%

54.88%

-4.27%

Volatility (1Y)

Calculated over the trailing 1-year period

80.82%

128.63%

-47.81%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

113.02%

115.34%

-2.32%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

113.02%

115.34%

-2.32%

Dividends

TOI vs. ANRO - Dividend Comparison

Neither TOI nor ANRO has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

TOI vs. ANRO - Financials Comparison

This section allows you to compare key financial metrics between The Oncology Institute, Inc. and Alto Neuroscience, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M20222023202420252026
147.44M
0
(TOI) Total Revenue
(ANRO) Total Revenue
Values in USD except per share items

Frequently Asked Questions


TOI and ANRO have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ANRO has higher volatility (24.73%) compared to TOI (21.02%). In terms of maximum drawdown, TOI dropped -98.79% vs ANRO's -91.82%.

ANRO currently has the higher Sharpe Ratio (7.25 vs 1.49), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TOI and ANRO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer